News
The company is leveraging its Antibody Warhead Enabling (AWE) technology platform to develop Antibody Radiation Conjugates (ARCs).
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback